AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Recruiting now · Phase 1/Phase 2
Conditions studied: Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse, Myelodysplastic Syndrome Acute Myeloid Leukemia
In brief
The primary objective is to define the safety and tolerability of AB8939 in patients with AML by determining the dose-limiting toxicities, the maximum tolerated dose, and the recommended dose for dose expansion study.
Key facts
- Study ID
- NCT05211570
- Run by
- AB Science
- People needed
- 78
- Starts
- 2022-06-01
- Expected to finish
- 2026-12-01
- Last updated by the study team
- 2025-10-02
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Virgen del Rocío University Hospital (Hospital Universitario Virgen del Rocío) — Seville, Spain (enrolling)
- MD Anderson Cancer Center Madrid — Madrid, Spain (enrolling)
- Clínica Universidad de Navarra — Pamplona, Spain (enrolling)
- National and Kapodistrian University of Athens NKUA · Department of Hematology and Bone marrow Transplantation Unit — Athens, Greece (enrolling)
- General University Hospital of Alicantet (Hospital General Universitario Dr. Balmis de Alicante) — Alicante, Spain (enrolling)
- Hospital San Pedro de Alcantara — Cáceres, Spain (enrolling)
- Hospital Universitario 12 de Octubre — Madrid, Spain (enrolling)
- Hospital Universitario Quirónsalud — Madrid, Spain (enrolling)
- Institut Paoli Calmettes — Marseille, France
- MD Anderson Cancer Center — Houston, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.